Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

For the Liu Lab, necessity is truly the mother of invention. The researchers were examining how the 3D organization of the ...

Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, ...

A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...

This listicle explores four major RNA therapeutic modalities, highlighting their breakthroughs, challenges and future ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development ...

Novigenix, a leader in AI-driven healthcare solutions, has published a groundbreaking study showcasing the predictive power of its LITOSeek™ platform for immunotherapy response in metastatic ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

As we continue to advance our Axiomer ADAR-mediated RNA editing platform and pipeline, ProQR is entering a pivotal phase of growth and ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...